CELGENE CORP /DE/
Form 425
February 20, 2019
Filed by Bristol-Myers Squibb Company
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934
Form S-4 File No.: 333-229464
Subject Company: Celgene Corporation
SEC File No.: 001-34912
Explanatory Note: The following slides were used by Bristol-Myers Squibb Company at an investor presentation on February 20, 2019.